Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
49
|
pubmed:dateCreated |
1996-1-17
|
pubmed:language |
ger
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0012-0472
|
pubmed:issnType |
Print
|
pubmed:day |
8
|
pubmed:volume |
120
|
pubmed:owner |
NLM
|
pubmed:pagination |
1721
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7497905-Clinical Trials, Phase I as Topic,
pubmed-meshheading:7497905-Clinical Trials, Phase II as Topic,
pubmed-meshheading:7497905-HIV Infections,
pubmed-meshheading:7497905-HIV Protease Inhibitors,
pubmed-meshheading:7497905-HIV-1,
pubmed-meshheading:7497905-Humans,
pubmed-meshheading:7497905-Isoquinolines,
pubmed-meshheading:7497905-Quinolines,
pubmed-meshheading:7497905-Saquinavir
|
pubmed:year |
1995
|
pubmed:articleTitle |
[The safety and efficacy of saquinavir in the therapy of HIV infection].
|
pubmed:publicationType |
Journal Article
|